| **Author, year** | **Intervention, n** | **Demographics** | **Age, in years** | **Disease characteristics** | **Disease activity index** | **Medications taken during study, %** | **Medications taken BEFORE study, %** | **Medications taken FOR INDUCTION, %** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Alemzadeh, 2002200 | Placebo, 108 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Alemzadeh, 2002200 | Corticosteroid, 27 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Beaugerie, 2009130 | Never user thiopurine, 10810Dose: NA | Male, %: 47Race NRSmoking NRCD, %: 48 | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 42.3 | Severity NRLocation, %Ileal: 33.3Colonic: 30.5Perianal: 7.3Behavior NRCRP NR | Disease activity index NR | TNF-alpha inhibitors: 0.6Methotrexate: 0.4Cyclosporin, mycophenolate mofetil, or cyclophosamide: 0.6 | TNF-alpha inhibitors: 0.9Methotrexate: 0.6 | NR |
| Beaugerie, 2009130 | Thiopurine, 8676Dose: NR | Male, %: 43Race NRSmoking NRCD, %: 76.1 | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation, %Ileal: 53.3Colonic: 59.3Perianal: 24.5Behavior NRCRP NR | Disease activity index NR | TNF-alpha inhibitors: 10Methotrexate: 7.5Cyclosporin, mycophenolate mofetil, or cyclophosamide: 1.6 | TNF-alpha inhibitors: 21.3Methotrexate: 15.3 | NR |
| Candy, 199553 | Azathioprine + Prednisolone, 33Route: Oral + OralDose: 2.5 mg/kg every day + 1 mg/kg every day | Male, %: 21Race NRSmoking, %Smoker, 67CD NR | Age at diagnosis NRDisease durationMedian: 2.6Min: 0.1Max: 19.3Age at enrollmentMedian: 33.9Min: 15Max: 60 | Severity, %Severe disease: 52Location, %Ileal: 24.2Ileo-colonic: 60.6Colonic: 15.2Behavior NRCRPMedian: 5.4Min: 2.9Max: 7.3 | CDAIMedian: 301Min: 264Max: 358 | Corticosteroids: 100Thiopurines: 100 | corticosteroids in previous 6-12 mo: 67no previous corticosteroids: 15: 15 | NR |
| Candy, 199553 | Placebo + Prednisolone, 30Route: Oral + OralDose: NA + 1 mg/kg every day | Male, %: 37Race NRSmoking, %Smoker, 67CD NR | Age at diagnosis NRDisease durationMedian: 3.7Min: 0.1Max: 18.7Age at enrollmentMedian: 31.8Min: 21Max: 62 | Severity, %Severe disease: 43Location, %Ileal: 20Ileo-colonic: 63.3Colonic: 16.7Behavior NRCRPMedian: 3.9Min: 2.8Max: 5.3 | CDAIMedian: 282Min: 240Max: 356 | Corticosteroids: 100 | Corticosteroidscorticosteroids in the last 6 months: 63no previous corticosteroids: 7: 7 | NR |
| Cezard, 2009194 | Placebo, 62 | Male, %: 58Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMean: 0.6Age at enrollmentMean: 11.6 | Severity NRLocation, %Ileal: 11Ileo-colonic: 69Colonic: 19Perianal: 31Behavior NRCRP NR | HBIMean: 0.9 | NR | NR | NR |
| Cezard, 2009194 | Mesalamine (Pentasa), 60Dose: 50 mg/kg every day | Male, %: 62Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMean: 1.1Age at enrollmentMean: 12 | Severity NRLocation, %Ileal: 13Ileo-colonic: 68Colonic: 18Perianal: 33Behavior NRCRP NR | HBIMean: 0.7 | NR | NR | NR |
| Crombe, 2011226EPIMAD | Infliximab + immunomodulator, 103 Route: Unknown + Unknown Dose: 5 mg/kg every 8 weeks + NR | Gender NRRace NRSmoking NRCD NR | NR | NR  | Disease activity index NR | 5ASACorticosteroids | NR | NR |
| Crombe, 2011226EPIMAD | Infliximab + no IMM, 17 Route: Unknown Dose: NA | Gender NRRace NRSmoking NRCD, %: 100 | NR | NR | Disease activity index NR | 5ASACorticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + Immunomodulator, 93 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | Corticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + No corticosteroids, 45 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | Immunomodulators | NR | NR |
| de Vries, 2008227 | Infliximab + No immunomodulator, 54 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | Corticosteroids | NR | NR |
| de Vries, 2008227 | Infliximab + Corticosteroid, 102 | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | Immunomodulators | NR | NR |
| D'Haens, 200848 | Budesonide + (6)-Methylprednisolone, 64Route: Oral + OralDose: 9 mg every days + 32 mg every day | Male, %: 42.2Race, %W: 95.3Smoking, %Current smoker, 35.9CD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 28.7 | Severity NRLocation, %Ileo-colonic: 43.8Colonic: 32.8Behavior NRCRPMedian: 25 | CDAIMean: 306IBDQMean: 136 | TNF-alpha inhibitorsCorticosteroidsMethotrexateThiopurinesBudesonide | 5ASA: 3.1 | NR |
| D'Haens, 200848 | Infliximab + Azathioprine, 65Route: IV + OralDose: 5 mg/kg + 2-2.5 mg/kg | Male, %: 33.8Race, %W: 98.5Smoking, %Current smoker, 43.1CD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 30 | Severity NRLocation, %Ileo-colonic: 47.7Colonic: 30.8Behavior NRCRPMedian: 19 | CDAIMean: 330IBDQMean: 122 | TNF-alpha inhibitors: 100MethotrexateAzathioprine: 100Methylprednisolone | 5ASA: 4.6 | NR |
| Escher, 2004190 | Prednisolone, 26Dose: 1 mg/kg every day | Male, %: 69.2Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMean: 0.8Age at enrollmentMean: 13 | Severity NRLocation, %Ileal: 26.9Ileo-colonic: 65.4Colonic: 3.8Behavior NRCRP NR | CDAIMean: 268PCDAIMean: 45 | NR | NR | NR |
| Escher, 2004190 | Budesonide, 22Dose: 9 mg every day | Male, %: 31.8Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMean: 0.6Age at enrollmentMean: 13 | Severity NRLocation, %Ileal: 59.1Ileo-colonic: 31.8Colonic: 9.1Behavior NRCRP NR | CDAIMean: 239PCDAIMean: 39 | NR | NR | NR |
| Griffiths, 1993221 | Mesalamine (Pentasa), 7Route: OralDose: 50 mg/kg every day | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | CDAIMean: 188.3HBIMean: 3.71 | NR | NR | NR |
| Griffiths, 1993221 | Placebo, 6Route: OralDose: NA every day | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | CDAIMean: 182.5HBIMean: 3.5 | NR | NR | NR |
| Issenman, 1993196 | Discontinued corticosteroids, 8 | Male, %: 100Race NRSmoking NRCD, %: 212.5 | Age at diagnosisMean: 13.2Disease duration NRAge at enrollmentMean: 13.2 | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Issenman, 1993196 | Prednisone, 9Route: OralDose: 2 mg/kg every days | Male, %: 100Race NRSmoking NRCD NR | Age at diagnosisMean: 14.5Disease duration NRAge at enrollmentMean: 14.5 | Severity NRLocation NRBehavior NRCRP NR | CDAIMean: 64.1 | Corticosteroids: 100 | 5ASA | NR |
| Lees, 2009145 | Adalimumab, 30 | Male, %: 36.7Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMedian: 32.3 | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Azathioprine, 51Route: IVDose: NR + NR | Gender NRRace NRSmoking NRCD, %: 100 | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Corticosteroid, 32Route: IV + UnknownDose: NR + NR | Gender NRRace NRSmoking NRCD, %: 100 | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Azathioprine/6-MP/methotrexate + corticosteroids, 55Route: IV + UnknownDose: NR + NR | Gender NRRace NRSmoking NRCD, %: 100 | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Lees, 2009145 | Infliximab + Never user concomitant azathioprine/6-MP/methotrexate/corticosteroids, 19Route: IVDose: NR | Gender NRRace NRSmoking NRCD, %: 100 | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Levine, 2002198 | Budesonide, 62Dose: 9 mg every day | Male, %: 59.7Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 14.1 | Severity NRLocation NRBehavior NRCRP NR | PCDAIMean: 25.8 | NR | immunomodulators: 29 | NR |
| Levine, 2002198 | Prednisone, 58Dose: 40 mg every day | Male, %: 60.3Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 13.7 | Severity NRLocation NRBehavior NRCRP NR | PCDAIMean: 29.6 | NR | immunomodulators: 20.6 | NR |
| Levine, 2003191 | Prednisone + Mesalamine, 14Dose: 40 mg every day + 3-4 g every day | Male, %: 50Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 14.15 | Severity NRLocation NRBehavior NRCRP NR | PCDAIMean: 28.9 | NR | NR | NR |
| Levine, 2003191 | Budesonide + Mesalamine, 19Dose: 3 mg every 8 hours + 3-4 g every day | Male, %: 68.4Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 13.8 | Severity NRLocation NRBehavior NRCRP NR | PCDAIMean: 29.3 | NR | NR | NR |
| Malik, 2011229Royal Hospital Sick Children | Infliximab + no steroid, 13 Route: IV Dose: 5 mg/kg every 2 weeks | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Methotrexate | NR | NR |
| Malik, 2011229Royal Hospital Sick Children | Infliximab + Methotrexate, 21 | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Corticosteroids | NR | NR |
| Malik, 2011229Royal Hospital Sick Children | Infliximab + no MTX, 7 | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Corticosteroids | NR | NR |
| Malik, 2011229Royal Hospital Sick Children | Infliximab + steroid, 15 | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Methotrexate | NR | NR |
| Markowitz, 2000192 | 6-MP + Prednisone, 27Dose: 1.5 mg/kg every day + 40 mg every day | Male, %: 55.6Race, %W: 93Smoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 13 | Severity NRLocation, %Ileal: 14.8Ileo-colonic: 70.4Colonic: 14.8Behavior NRCRP NR | PCDAIMean: 46.7HBIMean: 7.7partial HBMean: 6.6 | NR | NR | NR |
| Markowitz, 2000192 | Placebo + Prednisone, 28Dose: 40 mg every day | Male, %: 64.3Race, %W: 93Smoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollmentMean: 13.4 | Severity NRLocation, %Ileal: 3.6Ileo-colonic: 78.6Colonic: 17.9Behavior NRCRP NR | PCDAIMean: 44.7HBIMean: 7.4partial HBMean: 6.5 | NR | NR | NR |
| Mate-Jimenez, 200052 | 6-MP, 16Route: OralDose: 1.5 mg/kg every day | Gender NRRace NRSmoking, %Smoker, 75CD NR | Age at diagnosis NRDisease durationMean: 4.5Age at enrollment NR | Severity NRLocation, %Colonic: 37.5Perianal: 25Behavior NRCRP NR | CDAIMean: 191 | Corticosteroids: 100 | NR | NR |
| Mate-Jimenez, 200052 | Methotrexate, 15Route: OralDose: 15 mg every 1 week | Gender NRRace NRSmoking, %Smoker, 66.7CD NR | Age at diagnosis NRDisease durationMean: 4.3Age at enrollment NR | Severity NRLocation, %Colonic: 40Perianal: 20Behavior NRCRP NR | CDAIMean: 200 | Corticosteroids: 100 | NR | NR |
| Mate-Jimenez, 200052 | 5-ASA, 7Route: OralDose: 3 g every day | Gender NRRace NRSmoking, %Smoker, 85.7CD NR | Age at diagnosis NRDisease durationMean: 3.5Age at enrollment NR | Severity NRLocation, %Colonic: 14.3Perianal: 14.3Behavior NRCRP NR | CDAIMean: 215 | Corticosteroids: 100 | NR | NR |
| Present, 198060 | 6-MPRoute: UnknownDose: 1.5 mg/kg every 24 hours | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Present, 198060 | PlaceboRoute: OralDose: NA | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Rhodes, 197161 | Azathioprine, 16Route: OralDose: 4 mg/kg every 24 hours | Male, %: 75Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMin: 1Max: 14Age at enrollmentMin: 14Max: 69 | Severity NRLocation, %Ileal: 50Ileo-colonic: 37.5Colonic: 12.5Behavior NRCRP NR | Disease activity index NR | Sulfasalazine: 18.8Prednisolone: 18.8 | NR | NR |
| Rhodes, 197161 | Placebo, 16Route: OralDose: NA | Male, %: 75Race NRSmoking NRCD NR | Age at diagnosis NRDisease durationMin: 1Max: 16Age at enrollmentMin: 14Max: 69 | Severity NRLocation, %Ileal: 50Ileo-colonic: 37.5Colonic: 12.5Behavior NRCRP NR | Disease activity index NR | Corticosteroids: 18.8Sulfasalazine: 18.8 | NR | NR |
| Russell, 2011236 | Adalimumab + no IMM (Thio or MTX) +/- steroid, 24 Route: Unknown + Unknown Dose: 40 mg every 15 days + NR | Gender NRRace NRSmoking NRCD, %: 283.3 | NR | NR | Disease activity index NR | Corticosteroids | TNF-alpha inhibitorsCorticosteroidsMethotrexateThiopurinesImmunomodulators | NR |
| Russell, 2011236 | Adalimumab + IMM (Thio or MTX) +/- steroid, 46 Route: Unknown + Unknown Dose: NR | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Corticosteroids | TNF-alpha inhibitorsCorticosteroidsMethotrexateThiopurinesImmunomodulators | NR |
| Saha, 1998197 | Placebo | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Saha, 1998197 | Prednisone | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Infliximab | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Placebo | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Corticosteroid | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010199 | Methotrexate | Gender NRRace NRSmoking NRCD NR | Age at diagnosis NRDisease duration NRAge at enrollment NR | Severity NRLocation NRBehavior NRCRP NR | Disease activity index NR | NR | NR | NR |
| Thayu, 2010237CHOP | Corticosteroid | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Corticosteroids: 100 | NR | NR | 30 |
| Thayu, 2010237CHOP | No infliximab | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thayu, 2010237CHOP | No MTX | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thayu, 2010237CHOP | Infliximab | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | infliximab: 100 | NR | NR | 30 |
| Thayu, 2010237CHOP | Methotrexate | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | Methotrexate: 100 | NR | NR | 30 |
| Thayu, 2010237CHOP | No steroids | Gender NRRace NRSmoking NRCD NR | NR | NR | Disease activity index NR | NR | NR | NR | 30 |
| Thomson, 1990224 | Placebo, 105 Route: Oral Dose: NA every 8 hours | Male, %: 45.7Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration Mean: 5.3Age at enrollment Mean: 37.4 | NR | CDAI Mean: 60.1 | NR | sulphasalazine: 16.2 | NR | 2 |
| Thomson, 1990224 | 5-ASA, 101 Dose: 500 mg every 8 hours | Male, %: 42.6Race NRSmoking NRCD NR | Age at diagnosis NRDisease duration Mean: 6Age at enrollment Mean: 34.1 | NR | CDAI Mean: 51.8 | NR | sulphasalazine: 15.8 | NR | 2 |
| Van Assche, 200889 | Infliximab, 40Route: IVDose: 5 mg/kg every 8 weeks | Male, %: 47.5Race NRSmoking, %Smoker, 47.5CD NR | Age at diagnosis NRDisease durationMedian: 9Min: 2Max: 25Age at enrollmentMean: 35.4 | Severity NRLocation, %Colonic: 12.5Behavior NRCRPMedian: 3.2 | CDAIMean: 138.1 | TNF-alpha inhibitors: 100 | TNF-alpha inhibitors: 100MethotrexateThiopurines | NR |
| Van Assche, 200889 | Infliximab + Immunomodulator, 40Route: IV + OralDose: 5 mg/kg every 8 weeks + see below | Male, %: 42.5Race NRSmoking, %Smoker, 45CD NR | Age at diagnosis NRDisease durationMedian: 9Min: 1Max: 36Age at enrollmentMean: 35.6 | Severity NRLocation, %Colonic: 32.5Behavior NRCRPMedian: 3.4 | CDAIMean: 137.6 | TNF-alpha inhibitors: 100MethotrexateThiopurines | TNF-alpha inhibitors: 100MethotrexateThiopurines | NR |

Abbreviations: 5ASA = 5-aminosalicylic acid; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; CRP = C-reactive protein; g = gram; HBI = Harvey-Bradshaw Index; Max. = maximum; Min. = minimum; NA = not applicable; NR = not reported; TNF = tumor necrosis factor